TickerHumNASDAQ · Healthcare · Biotechnology
Regeneron Pharmaceuticals, Inc. (REGN)
As of Nov 11, 4:00 PM ET, Regeneron Pharmaceuticals (REGN) last traded at $959.41, up 4.73% on the day. Its TickerHum research score is 79/100 (above average). It reported revenue of $16.9B for the twelve months ending 2026-09-30, up 18.6% year over year, with a 28.8% operating margin.
Ratings
- Valuation: 78/100 — Based only on price / earnings (ttm) 21.2x.
- Growth: 59/100 — Strongest input: revenue growth (ttm, yoy) +18.6 %. Weakest: diluted eps growth (ttm, yoy) +8.4 %.
- Profitability: 79/100 — Strongest input: net margin 28.5 %. Weakest: return on equity 14.4 %.
- Financial health: 99/100 — Strongest input: current ratio 3.35. Weakest: long-term debt / equity 0.06.
- Momentum: 90/100 — Strongest input: price vs 200-day average +28.8 %. Weakest: 1-year return +40.7 %.
- Attention: 65/100 — Strongest input: headlines in the last 7 days 13. Weakest: volume vs 3-month average 1.6x.
- Risk resilience: 67/100 — Strongest input: annualised volatility (1y) 34.0 %. Weakest: max drawdown (1y) -26.1 %.
- Data confidence: 95/100 — Strongest input: quote age (hours) 14 h. Weakest: inputs available 85 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $16.9B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 18.6% | TTM ending 2026-09-30 · 10-Q |
| Net income | $4.82B | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $45.24 | TTM ending 2026-09-30 · 10-Q |
| Operating margin | 28.8% | TTM ending 2026-09-30 · 10-Q |
| Net margin | 28.5% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $3.83B | TTM ending 2026-09-30 · 10-Q |
| Cash | $3.66B | as of 2026-09-30 · 10-Q |
| Long-term debt | $1.99B | as of 2026-09-30 · 10-Q |
| Debt / equity | 0.06 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000872589).
Comparable companies for Regeneron Pharmaceuticals
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Regeneron Pharmaceuticals vs Moderna (REGN vs MRNA) — Same industry (Biotechnology); market cap unknown
- Regeneron Pharmaceuticals vs Vertex Pharmaceuticals (REGN vs VRTX) — Same industry (Biotechnology); market cap unknown
- Regeneron Pharmaceuticals vs Amgen (REGN vs AMGN) — Same sector (Healthcare), different industry; market cap unknown; shares: biologics
- Regeneron Pharmaceuticals vs AbbVie (REGN vs ABBV) — Same sector (Healthcare), different industry; market cap unknown
- Regeneron Pharmaceuticals vs Abbott Laboratories (REGN vs ABT) — Same sector (Healthcare), different industry; market cap unknown
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.